The Effect of Clinicopathological Features and Postoperative Management on Prognosis in Male Breast Cancer

IF 2.4 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Breast Journal Pub Date : 2026-10-09 DOI:10.1155/tbj/2806453

Shihe Liu, Qiying Song

{"title":"The Effect of Clinicopathological Features and Postoperative Management on Prognosis in Male Breast Cancer","authors":"Shihe Liu, Qiying Song","doi":"10.1155/tbj/2806453","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Background</h3>\n \n <p>Male breast cancer (MBC) represents a rare type of malignant tumor, comprising less than 1% of all breast cancer cases. Therapies for MBC patients are typically adapted from breast cancer treatments in women. This study systematically performed a retrospective evaluation of the clinicopathological features and prognostic determinants to offer evidence for a therapeutic strategy for MBC patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A total of 29 MBC patients were selected from PLA General Hospital in China from 2006 to 2023 and 2589 patients were retrieved from the Surveillance, Epidemiology, and End Results database with their registration periods spanning from 2016 to 2020. The clinicopathological features between different groups were compared using Pearson’s chi-square test (<i>χ</i><sup>2</sup> test) or Fisher’ s exact test, as appropriate. Multivariate Cox proportional hazards regression analysis was utilized to assess the predictors of overall survival (OS). Subgroup analyses were further conducted to evaluate the therapeutic efficacy across different stages.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 2618 patients totally. The primarily diagnosed median age of Chinese patients was younger than that of Western patients (59.8 years old vs 67.7 years old, <i>p</i> = 0.001). The infiltrating duct carcinoma was the most common pathological type for both groups. The subtypes (<i>p</i> = 0.622) and stages (<i>p</i> = 0.385) at diagnosis were similar between the two groups. Surgery at the primary site could improve the OS of MBC patients including Stage IV (<i>p</i> = 0.019). In stratified subgroup analyses, postoperative chemotherapy significantly improved OS in stages T2N1-3M0 and T3-4N1-3M0 MBC patients. Postoperative radiation was associated with favorable OS in early-stage (T1N0M0) and locally advanced (T3-4N1M0 and T1-4N2-3M0) MBC patients.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The median age at diagnosis for MBC patients in China was significantly younger compared to other populations. Postoperative chemotherapy significantly improved OS in patients with positive axillary lymph nodes and primary lesions exceeding 2 cm. Postoperative radiotherapy demonstrated survival benefits in partial early-stage and locally advanced patients. Additionally, surgery at the primary site represented a viable therapeutic option for selected Stage IV patients.</p>\n \n <p><b>Trial Registration:</b> Chinese Clinical Trial: ChiCTR2500110646</p>\n </section>\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2026 1","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/2806453","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/tbj/2806453","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Male breast cancer (MBC) represents a rare type of malignant tumor, comprising less than 1% of all breast cancer cases. Therapies for MBC patients are typically adapted from breast cancer treatments in women. This study systematically performed a retrospective evaluation of the clinicopathological features and prognostic determinants to offer evidence for a therapeutic strategy for MBC patients.

Methods

A total of 29 MBC patients were selected from PLA General Hospital in China from 2006 to 2023 and 2589 patients were retrieved from the Surveillance, Epidemiology, and End Results database with their registration periods spanning from 2016 to 2020. The clinicopathological features between different groups were compared using Pearson’s chi-square test (χ² test) or Fisher’ s exact test, as appropriate. Multivariate Cox proportional hazards regression analysis was utilized to assess the predictors of overall survival (OS). Subgroup analyses were further conducted to evaluate the therapeutic efficacy across different stages.

Results

We identified 2618 patients totally. The primarily diagnosed median age of Chinese patients was younger than that of Western patients (59.8 years old vs 67.7 years old, p = 0.001). The infiltrating duct carcinoma was the most common pathological type for both groups. The subtypes (p = 0.622) and stages (p = 0.385) at diagnosis were similar between the two groups. Surgery at the primary site could improve the OS of MBC patients including Stage IV (p = 0.019). In stratified subgroup analyses, postoperative chemotherapy significantly improved OS in stages T2N1-3M0 and T3-4N1-3M0 MBC patients. Postoperative radiation was associated with favorable OS in early-stage (T1N0M0) and locally advanced (T3-4N1M0 and T1-4N2-3M0) MBC patients.

Conclusions

The median age at diagnosis for MBC patients in China was significantly younger compared to other populations. Postoperative chemotherapy significantly improved OS in patients with positive axillary lymph nodes and primary lesions exceeding 2 cm. Postoperative radiotherapy demonstrated survival benefits in partial early-stage and locally advanced patients. Additionally, surgery at the primary site represented a viable therapeutic option for selected Stage IV patients.

Trial Registration: Chinese Clinical Trial: ChiCTR2500110646

查看原文本刊更多论文

男性乳腺癌临床病理特征及术后处理对预后的影响

男性乳腺癌（MBC）是一种罕见的恶性肿瘤，占所有乳腺癌病例的不到1%。对MBC患者的治疗通常改编自女性乳腺癌治疗。本研究系统地进行了临床病理特征和预后决定因素的回顾性评估，为MBC患者的治疗策略提供证据。方法选取2006 - 2023年中国人民解放军总医院收治的29例MBC患者，从2016 - 2020年监测、流行病学和最终结果数据库中检索2589例患者。不同组间临床病理特征的比较酌情采用Pearson卡方检验（χ2检验）或Fisher精确检验。采用多因素Cox比例风险回归分析评估总生存期（OS）的预测因素。进一步进行亚组分析，评估不同阶段的治疗效果。结果共发现2618例患者。中国患者的初诊中位年龄小于西方患者（59.8岁vs 67.7岁，p = 0.001）。浸润性导管癌是两组最常见的病理类型。两组诊断时的亚型（p = 0.622）和分期（p = 0.385）相似。原发部位手术可改善包括ⅳ期在内的MBC患者的OS （p = 0.019）。在分层亚组分析中，术后化疗显著改善T2N1-3M0期和T3-4N1-3M0期MBC患者的OS。术后放疗与早期（T1N0M0）和局部晚期（T3-4N1M0和T1-4N2-3M0） MBC患者的良好OS相关。结论：与其他人群相比，中国MBC患者的中位诊断年龄明显年轻。术后化疗可显著改善腋窝淋巴结阳性、原发病灶超过2 cm患者的OS。术后放疗显示了部分早期和局部晚期患者的生存益处。此外，在原发部位进行手术对于选定的IV期患者是一种可行的治疗选择。试验注册：中文临床试验：ChiCTR2500110646

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.